GIMOTI® (metoclopramide) nasal spray remains the sole FDA-approved treatment for diabetic gastroparesis, providing effective symptom relief and substantial cost savings compared to oral ...

As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI® (metoclopramide) is uniquely positioned to address the ongoing needs of patients ...

Its flagship product, GIMOTI, is the only FDA-approved nasal spray for this condition, offering reliable absorption by bypassing the digestive system—a critical benefit for patients with delayed ...

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report released on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® ...